Abstract
Historically radiotherapy (XRT) alone has been used to treat non-Hodgkin’s lymphoma (NHL) of limited extent [1]. The rationale for this approach has included the ability to eradicate tumor in a treatment field and the apparent success of this approach in limited stage Hodgkin’s disease (HD). However, it has become clear that the NHL are a diverse group of lymphoid neoplasms clearly distinguishable from HD. The prototype curable NHL is the large cell or ‘histiocytic’ lymphoma. This differs from HD in that it occurs in older patients, has a high growth fraction with a propensity for rapid hematogenous dissemination, and fails to exhibit the classic radiation dose-response curve [2]. Thus, it is not surprising that many, if not the majority of patients with large cell lymphoma, fail to be cured with radiotherapy alone [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Miller TP and Jones SE (1980). Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemother Pharmacol 4: 67–70.
Fuks Z and Kaplan HS (1973). Recurrence rates following therapy of nodular and diffuse malignant lymphomas. Radiology 108: 675–684.
DeVita VT, Canellos GP, Chabner BA et al. (1975). Advanced diffuse histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy. Lancet 1: 248–250.
McKelvey EM, Gottlieb JA, Wilson HE et al. (1976). Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493.
Jones SE, Grozea PN, Metz EN et al. (1979). Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma: A Southwest Oncology Group study. Cancer 43: 417–425.
Miller TP and Jones SE (1979). Chemotherapy of localized histiocytic lymphoma. Lancet 1: 358–360.
Cabanillas F, Bodey GP and Freireich EJ (1980). Management with chemotherapy only of Stage I and II malignant lymphoma of aggressive histologic types. Cancer 46: 2356–2359.
Miller TP and Jones SE (1983). Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 62: 413–418.
Bonadonna G, Bajetta E, Lattuada A et al. (1984). CVP vs BACOP chemotherapy sequentially combined with irradiation in Stage I-II diffuse non-Hodgkin’s lymphomas. In: Jones SE and Salmon SE (Eds.). Adjuvant Therapy of Cancer. IV. New York: Grune and Stratton. In press.
Skarin AT, Canellos GP, Rosenthal DS et al. (1983). Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents ( M-BACOD ). J Clin Oncol 1: 91–98.
Skarin A, Cannellos G, Rosenthal D et al. (1983). Moderate dose methotrexate (m) combined with bleomycin (B), adriamycin (A), cyclophosphamide (C), oncovin (o) and dexamethasone (D), (m-BACOD), in advanced diffuse histiocytic lymphoma ( DHL ). Proc Amer Soc Clin Oncol 2: 220.
Fisher RI, DeVita VT, Hubbard SM et al. (1983). Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 98: 304–309.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Jones, S.E., Miller, T.P. (1985). The use of chemotherapy for localized large cell lymphoma. Results from the University of Arizona. In: Cavalli, F., Bonadonna, G., Rozencweig, M. (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Developments in Oncology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2607-6_50
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2607-6_50
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9632-4
Online ISBN: 978-1-4613-2607-6
eBook Packages: Springer Book Archive